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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comfemoropopliteal (fem-pop) artery disease with drug-coated balloons (DCB)
vs. standard PTA. The overall impact of DCB use on medical care costs is
unknown.
Methods: We performed a prospective economic study alongside the IN.PACT SFA
II trial, which randomized patients with symptomatic fem-pop disease to DCB vs.
standard PTA and followed them for a minimum of 12 months. Detailed medical
resource utilization data were collected and costs were assigned for all US patients
using resource-based accounting (for revascularization procedures, medications and
outpatient vascular care) and hospital billing data for costs associated with the index
and follow-up hospitalizations for treatment of the target limb. The DCB was assigned
a cost of $1350/balloon.
Results: A total of 181 US patients were enrolled (121 DCB, 60 PTA). Initial hospital
costs were approximately $1100/patient higher in the DCB group than the PTA group
($8258 vs. $7164, p< 0.001), driven mainly by the cost of the DCB itself (see Table).
From discharge through 12 months, follow-up target-limb related medical care costs
werew$750/pt lower in the DCB group, such that total 1-year costs were similar for
the 2 groups ($10,034 vs. $9694, p¼0.82) with a resulting incremental cost-effec-
tiveness ratio of $2906 per repeat revascularization avoided - similar to that for cor-
onary drug-eluting stents.DCB
(n¼121)
Standard
PTA (n¼60) p-value
Index Procedure
and Hospitalization
Standard PTA balloons 1.3  0.5 2.3  0.7 <0.001
Drug-coated balloons 1.4  0.6 0.0  0.0 <0.001
Stents 0.1  0.3 0.2  0.5 0.067
Index procedure costs $5918  2425 $4604  2331 <0.001
Index hospitalization costs $8258  3223 $7164  3325 0.002
12-Month Follow-up
TVR events (per 100 pts) 11.6 76.6 23.3  62.1 0.005
Target limb
hospitalization-related costs
$1324  9148 $1975  5260 0.002
Medication costs $348  440 $344  277 0.378
Physician fees $104 574 $211  522 0.002
Total follow-up costs $1777  9699 $2530  5823 0.067
Total 1-year costs $10,034  10836 $9694  6884 0.459Conclusions: For patients with symptomatic fem-pop disease, use of the DCB was
associated with higher initial costs compared with standard PTA, but these were
largely offset by lower costs for follow-up target limb procedures through 1-year of
follow-up. The cost-effectiveness of DCB for such patients appears to compare
favorably with that for other cardiovascular interventions.
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Restenosis. Does debulking matter?
Sasanka Jayasuriya1, Carlos I. Mena1
1Yale University, New Haven, CT
Background: In-stent restenosis (ISR) after femoropopliteal artery stenting is a
signiﬁcant problem occurring in up to 50% of cases. The EXCITE ISR trial aimed
to demonstrate that procedural safety and efﬁcacy after debulking ISR lesions
with laser atherectomy is superior to balloon angioplasty (PTA) alone. Procedur-
ally, the Turbo Elite laser catheter (Spectranetics Inc., Colorado Springs, CO.) was
used to recanalize the ISR lesion prior to additional debulking with the Turbo
Tandem (Spectranetics Inc., Colorado Springs, CO) laser catheter. In this sub
analysis, outcomes were evaluated when optimal debulking is achieved with Turbo
Elite.
Methods: Angiographic residual stenosis post-Turbo Elite was available for 95 pa-
tients. Group 1 consisted of 25 patients in which atherectomy with Turbo Elite ach-
ieved 30% residual stenosis prior to any additional debulking with Turbo Tandem or
PTA treatment. Group 2 consisted of 70 patients in which 30% residual stenosis was
not achieved with Turbo Elite. Lesion characteristics and freedom from TLR through
6 months follow up is evaluated.
Results: Lesion length was similar: 19.5 cm vs 20.9 cm, Group 1 vs Group 2
respectively. Baseline diameter stenosis was similar (85% vs 89%; Group 1 vs Group
2), however there were more occlusions in Group 2 (28% vs 36%, p¼ns). Procedural
complications were similar for both groups as well as the average number of Turbo
Elite lasing trains. In amenable lesions (Group 1), there is little additional luminal
gain with Turbo Tandem or PTA after optimal debulking with Turbo Elite (table).
Furthermore, freedom from TLR is improved in Group 1. However, this is a statisticalB156 JACC Vol 64/1trend due to the low number of events until additional patients can be followed thru
6 months.Conclusions: Conclusions: This sub analysis of the EXCITE ISR trial demonstrates
that if optimal debulking is achieved with Turbo Elite, additional therapy is not
necessary.
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Background: Peripheral artery disease (PAD) has major worldwide health impact.
Stellarex (Covidien, Mansﬁeld, MA, USA) is an experimental paclitaxel-coated
PTA balloon designed for use in patients with PAD. The ILLUMENATE ﬁrst in
human (FIH) study was conducted at two German sites and enrolled patients with
superﬁcial femoral and/or popliteal artery lesions. Patients were followed for 24
months. This analysis was conducted to estimate the economic impact of the Stel-
larex drug-coated balloon (DCB) vs. uncoated PTA (PTA) at 12- and 24-month
follow-up.
Methods: Data from the ILLUMENATE FIH pre-dilatation cohort was compared
with a pooled and weighted PTA cohort from historical data. Costs for the baseline
procedure and clinically-driven target lesion revascularizations (TLRs) were
assigned to both groups using the 2013 German G-DRG reimbursement tariffs.
Budget impact models were constructed for 12- and 24-month follow up based on
total cost of the baseline procedure plus TLR (determined by TLR rates) in both
groups.
Results: The Stellarex (n¼50) and the pooled PTA cohorts (n¼139) were balanced
with respect to baseline characteristics. Between 12 and 24 months there were no
additional TLR events for the DCB treated patients while there were 17 additional
TLR’s in PTA patients. The budget impact model demonstrated cost advantages for
Stellarex through 24 months. At 12 months, a patient treated with Stellarex cost
w450V less than PTA (3575V vs. 4027V); at 24 months the difference increased to
w800V (3611V vs 4409V). Extrapolated to 25,000 PAD patients, the use of
Stellarex has the potential to save the healthcare system over 11,000,000V at 12
months and nearly 20,000,000V at 24 months. The number of patients treated with
Stellarex (compared to PTA) to prevent one TLR was 4 at 12 months and 3 at 24
months.
Conclusions: An initial treatment strategy using the Stellarex DCB was associated
with reduced long term TLR between 12 and 24 months vs. PTA. This has the po-
tential to result in a signiﬁcant reduction in healthcare expenditures through two years
post-treatment. Prospective, comparative outcomes data are needed to validate this
model.
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Background: We explored the incidence and pattern of repeat peripheral vascular
intervention (PVI) procedures in patients with peripheral arterial disease (PAD).
Methods:We studied patients undergoing percutaneous PVI in 2012 and 2013 among
47 Hospitals in Michigan that participate in the BMC2 - VIC registry. To identify
return visits, we applied a matching algorithm that used Date of Birth, Gender, Zip
code, and Race.
Results: Of 18381 total PVI procedures, 3263 (17%) patients had multiple PVIs and
these patients accounted for 7720 (42%) of all PVIs in the cohort. Of the multiple PVI
patients, 235 (7.4%) had a PVI on the same vessel as the index PVI, 551 (17.4%) had
PVI on both the same and an additional vessel, and 2377 (75.2%) had PVI on a
different vascular bed. 94% of the PVIs performed in the entire cohort were on lower
extremity (LE).The most frequently used devices for initial LE PVI were balloon (B),1/Suppl B j September 13–17, 2014 j TCT Abstracts/Iliac and SFA
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMballoon and stent (BS), and atherectomy and balloon (AB) (B-29%, BS-27%, and AB-
31%). In repeat PVI, B and BS use were different from the initial PVI (B 39%, BS
17%, respectively p< 0.001), and AB use was not different (34%, p¼0.2). A network
plot of device use and change from initial to repeat procedure is shown (p< 0.001 for
pattern).Conclusions: In a contemporary PAD patient population, multiple PVI procedures
occur commonly, but the majority are procedures in a different vascular bed. Repeat
PVI in the same vessel occurs less often. Balloon angioplasty remains the dominant
procedure for both the initial or repeat LE PVI, either as stand-alone therapy or in
combination with stent or atherectomy.
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Background: Peripheral endovascular intervention (PVI) has changed the treat-
ment landscape for patients with PAD. The primary aim of this analysis is to
understand the trends and variation in PVI after changes in Medicare Coverage
Determination (MCD) in 2008 that affect professional and technical reimbursement
rates for PVI.
Methods: We utilized a 5% sample of Medicare beneﬁciaries from 2006 to 2011, and
patients were required to have a procedure code for revascularization and a diagnosis
code for PAD. Rates of revascularization were age- and sex-adjusted to the Medicare
fee-for-service population. Rates by treatment location, year, and physician specialty
were reported per 100,000 beneﬁciaries.
Results: 39,339 patients underwent revascularization for PAD and were included in
the analysis. The PVI rate increased from 4,986 in 2006 to 5,548 in 2011, while the
rate of surgical revascularization decreased from 1,562 in 2006 to 1,172 in 2011
[Panel A]. Surgeons (50%) and cardiologists (33%) performed the majority of PVI
[Panel B]. The rate of PVI performed in inpatient settings declined signiﬁcantly while
the rate of PVI performed in outpatient hospital settings and ofﬁce-based clinics
increased signiﬁcantly [Panel C]. The use of atherectomy increased 50-fold in ofﬁce-
based clinics since 2006.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/IliaConclusions: The overall rates of PVI increased by 10%, mostly performed by
surgeons and cardiologists. PVI and especially atherectomy use in outpatient set-
tings increased dramatically, highlighting possible unintended consequences of
coverage decisions and need for studies demonstrating beneﬁt for endovascular
technologies.
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Background: Endovascular approach to superﬁcial femoral artery (SFA) disease, the
most common cause of symptomatic PAD, remains fraught with high failure rates.
Newer devices including second-generation nitinol stents, drug-coated stents, drug-
coated balloons, covered stents, cryo-therapy, LASER and directional atherectomy,
have shown promising results. Clinical equipoise still persists regarding the optimal
selection of devices, largely attributable to the different inclusion criteria, study
population, length of lesions treated, deﬁnition of “patency” and “restenosis” and
follow-up methods in the pivotal trials.
Methods: A prospective protocol was developed. We performed a literature search
using PubMed from January 2006 – November 2013. Published articles including
endovascular interventions in SFA or popliteal arteries with reported 12-month “pri-
mary patency” or “binary restenosis” rates as endpoints were included.
Results: We identiﬁed 6024 patients in 61 trials reporting 12-month primary patency
rates in patients with femoropoliteal disease. Primary patency rates were (weighted
average) 78% for nitinol stents, 68.8% for Covered stents, 84% for Drug eluting
stents, 78.2% for DEB, 60.7% for cryoballoon, 51.1% for LASER atherectomy,
63.5% for directional atherectomy and 70.2% with a combination of endovascular
devices.
Conclusions: The most frequently used endovascular devices yielded various
12-month primary patency rates ranging from 51% to 85%. The increased variation in
inclusion criteria, length and complexity of lesions between studies does not allow
direct comparison between them. Larger randomized trials in speciﬁc patient pop-
ulations comparing those modalities is needed before we can make safe recommen-
dation of the superiority of one device over the other.
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Background: Case series where the use of optical coherence tomography (OCT)
greatly reduced or eliminated ﬂuoroscopy during the crossing of peripheral arterial
chronic total occlusions (CTOs) when using the Ocelot catheter (Avinger Inc, CA).
Methods: Fifteen patients, with sixteen lesions (n¼16) were successfully treated for
peripheral arterial CTOs between January 2013 and June 2013. Ocelot imaging
identiﬁes arterial structures to guide catheter crossing within the true lumen. By
placing the middle marker over arterial structures, the catheter tip is deﬂected in the
opposite direction towards atheroma (Figure 1). Time measurements were recorded for
diagnostic angiography, CTO crossing ﬂuoroscopy, and therapeutic ﬂuoroscopy
times.c and SFA B157
